Liver transplantation for an HIV-positive patient in the era of highly active antiretroviral therapy [3]

AIDS

Volumn 15, Issue 2, 2001, Pages 291-292

  Gow, P J ^a   Mutimer, D ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; NEVIRAPINE; SAQUINAVIR; STAVUDINE; TACROLIMUS;

ADULT; APPENDECTOMY; CASE REPORT; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEMOPHILIA A; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LETTER; LIPODYSTROPHY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV SEROPOSITIVITY; HUMANS; LIVER TRANSPLANTATION; MALE; TREATMENT OUTCOME;

EID: 0035951499     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200101260-00029     Document Type: Letter

References (5)

1. Transplantation in HIV+ patients
2. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1
3. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers
4. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels
5. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HW and hepatitis C virus (HCV)